Statement Of Financial Position [Abstract]

ERYTECH Pharma S.A. - Filing #2810992

Concept As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
Statement of financial position [abstract]
Assets [abstract]
Non-current assets [abstract]
Property, plant and equipment
1 004 EUR
393,000 EUR
18 960 EUR
Right-of-use assets
2 895 EUR
2 584 EUR
6 869 EUR
Goodwill
9 622 EUR
EUR
EUR
Intangible assets other than goodwill
21 362 EUR
5,000 EUR
15,000 EUR
Non-current assets
35 088 EUR
3 177 EUR
26 720 EUR
Current assets [abstract]
Current inventories
EUR
EUR
EUR
Cash and cash equivalents
10 474 EUR
38 789 EUR
33 699 EUR
44 446 EUR
Current assets
16 219 EUR
42 634 EUR
40 048 EUR
Assets
51 307 EUR
45 811 EUR
66 768 EUR
Equity and liabilities [abstract]
Equity [abstract]
Issued capital
6 075 EUR
3 102 EUR
3 102 EUR
Share premium
49 671 EUR
48 975 EUR
97 618 EUR
Equity attributable to owners of parent
25 612 EUR
7 836 EUR
23 488 EUR
49 672 EUR
6 075 EUR
1 189 EUR
23 487 EUR
29 765 EUR
228,000 EUR
48 975 EUR
3 102 EUR
1 402 EUR
53 797 EUR
22 845 EUR
25 293 EUR
97 618 EUR
1 215 EUR
3 102 EUR
2 006 EUR
1 744 EUR
73 300 EUR
24 616 EUR
120 705 EUR
26 539 EUR
Liabilities [abstract]
Non-current liabilities [abstract]
Non-current provisions [abstract]
Non-current provisions
1 051 EUR
419,000 EUR
524,000 EUR
Deferred tax liabilities
EUR
EUR
EUR
Non-current liabilities
10 429 EUR
10 646 EUR
23 918 EUR
Current liabilities [abstract]
Current provisions [abstract]
Current provisions
96,000 EUR
314,000 EUR
EUR
Trade and other current payables
7 104 EUR
5 115 EUR
14 154 EUR
Current liabilities
15 264 EUR
11 678 EUR
20 005 EUR
Equity and liabilities
51 307 EUR
45 811 EUR
66 768 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.